<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <title>Submission 512 from Anon (session_user_id: 869c33ac2a30f9525172ffd088b853d2fc9d811f)</title>
    <link href="../../../export.css" rel="stylesheet">
  </head>
  <body>
    <h1>Submission 512 from Anon (session_user_id: 869c33ac2a30f9525172ffd088b853d2fc9d811f)</h1>
    <div class="field-name" id="d6002606a5ec3d03">Q1. Describe how DNA methylation is altered in cancer.
In your answer include the following points:
<br><p></p><ul><li>Describe the normal
function of DNA methylation at CpG islands.<br></li><li>Describe how DNA
methylation of CpG islands is disrupted in cancer.<br></li><li>Explain how disruption of
DNA methylation at CpG islands contributes to cancer.<br></li><li>Describe the normal
function of DNA methylation in intergenic regions and repetitive elements.<br></li><li>Describe how DNA
methylation in intergenic regions and repetitive elements is disrupted in cancer.<br></li><li>Explain how disruption
of DNA methylation in intergenic regions and repetitive elements contributes to
cancer.<br></li></ul><p></p></div>
    <div class="field-value"><p><span><span><span><span lang="en-us" xml:lang="en-us">I</span></span><span>n         a normal cell </span><span><span lang="en-us" xml:lang="en-us">CpG         islands in promoter reg</span></span><span><span lang="en-us" xml:lang="en-us">ions         are </span></span><span><span lang="en-us" xml:lang="en-us">not         methylated. </span></span><span>In contrast,  </span><span>in         cancer cells promoter CpG islands tend to become hypermethylated,         which then causes silencing of the underlying gene.</span><span><span lang="en-us" xml:lang="en-us">         The </span></span><span><span lang="en-us" xml:lang="en-us">hypermethylat</span></span><span><span lang="en-us" xml:lang="en-us">ion         of  </span></span><span>CpG island shores, defined         as approximately 2 kb regions surrounding CpG islands,  </span><span>a</span><span><span lang="en-us" xml:lang="en-us">lso         </span></span><span><span lang="en-us" xml:lang="en-us">was shown </span></span><span>in         cancer </span><span><span lang="en-us" xml:lang="en-us">cells</span></span><span>.</span><span>         </span></span></span>       </p>
<p><span><span><span><span><span lang="en-us" xml:lang="en-us">H</span></span><span>ypermethylation         of  CpG islands </span><span><span lang="en-us" xml:lang="en-us">in         </span></span><span>promoter</span><span><span lang="en-us" xml:lang="en-us">s</span></span><span>         of tumor suppressor genes causes silencing </span><span><span lang="en-us" xml:lang="en-us">of         these genes </span></span><span><span lang="en-us" xml:lang="en-us">by         e formation of a repressive chromatin structure or (and) prohibit         transcription factor binding .</span></span><span>         </span><span><span lang="en-us" xml:lang="en-us">H</span></span><span>ypermethylation         </span><span><span lang="en-us" xml:lang="en-us">in </span></span><span>CpG         island shores </span><span><span lang="en-us" xml:lang="en-us">and         </span></span><span><span lang="en-us" xml:lang="en-us">in </span></span><span>imprint         control regions (ICRs) </span><span><span lang="en-us" xml:lang="en-us">may         </span></span><span><span lang="en-us" xml:lang="en-us">also </span></span><span><span lang="en-us" xml:lang="en-us">alter         gene expression.</span></span></span></span></span></p>
<p>        <span><span><span><span><span lang="en-us" xml:lang="en-us">D</span></span><span>isabling         of genes that are critically important to controlling cell         proliferation contributes to the development of a malignant         phenotype in the same manner as inactivating mutations of tumor         suppressor genes. Epigenetic silencing by DNA methylation of         cyclin-dependent kinase inhibitors, DNA repair genes, apoptosis         mediators, nuclear receptors, transcription factors, cell adhesion         molecules, and many other genes has been reported in multiple cancer         types. Perhaps the most convincing evidence for CpG island         methylation causing the same harmful effect as inactivating         mutations of tumor suppressor genes in cancer is documented in         studies describing RB1, p16 (CDKN2A), VHL, and MLH1 genes. Each of         these genes can be inactivated by either DNA methylation or a         mutation with equal consequences for cancer development.</span></span></span></span></p>
<p>        <span><span><span><span lang="en-us" xml:lang="en-us">I</span>n         a normal cell the genome in general is methylated in the repetitive         elements<span lang="en-us" xml:lang="en-us">,</span><br />through the intergenic         regions and  even in the introns of genes </span></span></span>       </p>
<p><span><span><span>In         cancer cells  repetitive elements, intergenic regions and even         introns are hypomethylated. </span></span></span>       </p>
<p><span><span><span>Genome-wide         hypomethylation <span lang="en-us" xml:lang="en-us">o</span>ccurs to some degree in         all tumour types tested, progresses with tumorigenicity.         Consequence of hypomethylation depends on location<span lang="en-us" xml:lang="en-us">:         in r</span>epeats <span lang="en-us" xml:lang="en-us">and i</span>ntergenic regions         <span lang="en-us" xml:lang="en-us">it causes</span> genomic instability <span lang="en-us" xml:lang="en-us">(</span>a         characteristic feature <span lang="en-us" xml:lang="en-us">for </span>many <span lang="en-us" xml:lang="en-us">mice         and</span> human cancers<span lang="en-us" xml:lang="en-us">)</span> , <span lang="en-us" xml:lang="en-us">in         </span>CpG poor promoters <span lang="en-us" xml:lang="en-us">-</span> oncogene         activation </span></span></span></p></div>

    <div class="field-name" id="323cdd9789545f83">Q2. Describe how disruption of imprinting can contribute to cancer, using the example of the H19/Igf2 cluster. In your
answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe the methylation pattern of the paternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe the methylation pattern of the maternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe how imprinting at the H19/Igf2 cluster is disrupted in Wilm’s tumour.&nbsp;
        <br>
    </li>
    <li>Explain how disrupting imprinting at the H19/Igf2 cluster contributes to cancer.
        <br>
    </li>
</ul></div>
    <div class="field-value"><p lang="en-us" xml:lang="en-us"><span style="font-family:'Times New Roman';"><span style="font-size:medium;">When the imprinting control region within the Igf2–H19 locus is unmethylated, as found on maternal chromosomes,CTCF binds to the insulator element between the two genes. The insulator–CTCF complex acts to block the Igf2 gene from the enhancer that is positioned 3′ of H19. As a consequence, only the H19 gene is active. When the imprinting control region and the H19 gene are methylated, as found on paternal chromosomes, several events occur. CTCF fails to bind to the insulator and so the 3′enhancer can activate the Igf2 promoter. <br />On the paternal allele, because this is methylated,  the enhancers can act on IGF2, because CTCF is not binding to isulate this, and IGF2 is expressed from the pattern allele. <br />However, with loss of imprinting and what happened is you have high permethylation of the imprint control region on the maternal allele as well. Now Igf2 expresses on the maternal allele also. <br />So now it'll be a double dose of <span style="color:#ff3366;">the</span><span style="color:#ff3366;"> oncogene </span>Igf2 than in a normal cell and<br />this is associated with Wilm's tumour. </span></span></p></div>

    <div class="field-name" id="961ab4c640df430a">Q3. The Economist article “<a href="http://www.economist.com/node/21552168" target="_blank">Cancer’s epicentre</a>” describes several drugs that affect
    epigenetic processes. Explain how Decitabine may be used to treat cancer,
    with reference to effects on the epigenome. In your answer include the
    following points:
<br>
<p></p>
    <ul>
        <li>Identify the class of epigenetic inhibitors that Decitabine belongs to.&nbsp;
            <br>
        </li>
        <li>Describe the impact of Decitabine on DNA methylation.
            <br>
        </li>
        <li>Describe how Decitabine can have an anti-tumour effect.&nbsp;
            <br>
        </li>
    </ul></div>
    <div class="field-value"><p><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;">The         pyrimidine analog Decitabine belongs to DNA methyltransferase         </span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;" lang="en-us" xml:lang="en-us">inhibitors </span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;" lang="en-us" xml:lang="en-us">(</span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;" lang="en-us" xml:lang="en-us">DNMT</span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;"> i</span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;" lang="en-us" xml:lang="en-us">)</span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;"> , cause</span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;" lang="en-us" xml:lang="en-us">s</span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;"> DNA         demethylation </span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;" lang="en-us" xml:lang="en-us">by</span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;"> irreversibly bind</span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;" lang="en-us" xml:lang="en-us">ing</span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;" lang="en-us" xml:lang="en-us">         </span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;">DNA methyltransferases after they are incorporated into DNA.         DNA demethylation lead</span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;" lang="en-us" xml:lang="en-us">s</span><span style="font-size:medium;font-family:'Times New Roman';color:#000000;font-weight:bold;line-height:21px;"> to a consecutive         reactivation of epigenetically silenced tumor suppressor genes in         vitro and in vivo.</span><span style="font-weight:bold;line-height:21px;font-size:14px;">        </span><span style="color:#000000;"><span style="font-family:'Times New Roman';"><span style="font-size:medium;"><span lang="en-us" xml:lang="en-us">Decitabine         </span><span lang="en-us" xml:lang="en-us"> is</span> replication dependent <span lang="en-us" xml:lang="en-us">and         not </span> selective for the cancer cells.</span></span></span><span style="font-weight:bold;line-height:21px;font-size:14px;">      In</span><span style="color:#000000;"><span style="font-family:'Times New Roman';"><span style="font-size:medium;"><span lang="en-us" xml:lang="en-us">    </span>combination  <span lang="en-us" xml:lang="en-us">with         </span>histone-deacetylase inhibitor  it     showed an unexpectedly good reaction to the routine         chemotherapeutic drugs . <span lang="en-us" xml:lang="en-us">The         </span>epigenetic drugs altered the tumour cells in some lasting way    that made them more susceptible to standard chemotherapy, <span lang="en-us" xml:lang="en-us">because     </span>epigenetic changes are passed on during cell division to   daughter and granddaughter cells until they are actively erased.         Once erased, though, they do not return. It might therefore be that         epigenetic therapies can effect changes which stop a cancer growing         without having to kill all its cells.</span></span></span></p>
<dl><dt></dt></dl></div>

    <div class="field-name" id="10aa9d89e69a5f7a">Q4. Dr Stephen Baylin speculates in the Economist article that "epigenetic
drugs altered the tumour cells in some lasting way that made them more
susceptible to standard chemotherapy." How can drugs that alter DNA methylation
have effects that last beyond the period of drug treatment? Discuss whether
there are any periods of development when you would avoid treating patients
with such drugs. In your answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe how altering DNA methylation can have enduring effects on the
        epigenome.
        <br>
    </li>
    <li>Define what is meant by a sensitive period.
        <br>
    </li>
    <li>Identify sensitive periods of development.
        <br>
    </li>
    <li>Explain why treating patients during sensitive periods would be inadvisable.
    <br>
</li>
</ul></div>
    <div class="field-value"><p><span style="color:#444444;">A</span><span style="font-size:medium;"><span><span style="font-family:'Times New Roman';"><span>ltering         DNA methylation </span></span></span><span style="color:#444444;"><span style="font-family:'Times New Roman';"><span><span lang="en-us" xml:lang="en-us">caus</span></span></span></span><span style="color:#444444;"><span style="font-family:'Times New Roman';"><span><span lang="en-us" xml:lang="en-us">es         the </span></span></span></span><span style="color:#444444;"><span style="font-family:'Times New Roman';"><span><span lang="en-us" xml:lang="en-us">inactivating         of tumor suppressor genes in cancer, </span></span></span></span><span style="color:#444444;"><span style="font-family:'Times New Roman';"><span><span lang="en-us" xml:lang="en-us">leads         to</span></span></span></span><span style="color:#444444;"><span style="font-family:'Times New Roman';"><span><span lang="en-us" xml:lang="en-us">           </span></span></span></span><span style="color:#444444;"><span style="font-family:'Times New Roman';"><span><span lang="en-us" xml:lang="en-us">e</span></span></span></span><span style="color:#444444;"><span style="font-family:'Times New Roman';"><span><span lang="en-us" xml:lang="en-us">pigenetic</span></span></span></span><span style="color:#444444;"><span style="font-family:'Times New Roman';"><span>         silencing  of cyclin-dependent kinase inhibitors,         DNA repair genes, apoptosis mediators, nuclear receptors,         transcription factors, cell adhesion molecules and many other genes         that are critically important to controlling cell proliferation         contributes to the development of a malignant phenotype. </span></span></span></span><span style="font-weight:bold;line-height:21px;font-size:14px;">      </span><span style="font-family:'Times New Roman';"><span style="font-size:medium;"><span style="color:#444444;">DNA         demethylating drugs restore "normal" pattern of         methylation, which is transmitted and grand-daughter cells at         division. This may explain the continued positive effect of         epigenetic therapy. </span></span></span><span style="font-weight:bold;line-height:21px;font-size:14px;">        </span></p>
<dl><dt><span style="font-family:'Times New Roman';"><span style="font-size:medium;"><span style="color:#444444;">However         it is known that these patterns of DNA methylation does not exist at         all stages of development, they are erased in the early embryonic         development (from zygote to blastocyst), and in primordial germ         </span><span style="color:#444444;"><span lang="en-us" xml:lang="en-us">cells </span></span><span style="color:#444444;">formation.         </span><span style="color:#444444;">During these periods, the development         of the epigenome is extremely sensitive to different influences and         interference in the epigenetic machinery will certainly be harmful .         </span><span style="color:#444444;">This will lead to abnormalities in gene         regulation. </span><span style="color:#444444;">Therefore, in these         sensitive periods when the active cell division occurs, </span><span style="color:#333333;">if         they are given to a very young child and  to a pregnant woman</span><span style="color:#333333;">,</span><span style="color:#444444;">         the DNA demethylating drug should be used with great caution.</span><span style="color:#333333;">         We would expect potentially serious side effects to the fetus.         There is this potential for harm.</span></span></span></dt></dl><dl><dt><span style="color:#444444;font-size:medium;font-family:'Times New Roman';line-height:21px;">     </span></dt></dl></div>
  </body>
</html>